Experimental combo vaccine and drugs show promise for blood cancers
NCT ID NCT03358719
First seen Mar 13, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This early-phase trial tested a combination of a cancer vaccine (CDX-1401), an immune booster (poly ICLC), chemotherapy (decitabine), and an immunotherapy drug (nivolumab) in 8 people with myelodysplastic syndrome (MDS) or low-blast acute myeloid leukemia (AML). The main goal was to check safety and side effects. Researchers also looked at how the treatment affected the immune system and cancer cells. The study is complete, but results are not yet widely reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.